Particle Sciences acquires PEG-based polymer technology
US-based CRO adds to portfolio of drug delivery technologies
Particle Sciences Inc (PSI), a US-based pharmaceutical contract research organisation (CRO), has expanded its drug delivery technologies portfolio with the acquisition of a PEG-based technology. The technology covers a series of PEG-grafted cationic polymers, which have a variety of applications in the pharmaceutical industry.
‘PEGylation is a recognised approach to stabilise drug suspensions, improve drug solubility and bioavailability, and reduce toxicity and reticuloendothelial system interaction,’ said Robert Lee, VP of pharmaceutical development at PGI. ‘The technology we have acquired covers a set of novel, biocompatible PEGylated polymers allowing the PEGylation of particles and biological surfaces.’
Particle Sciences is an integrated provider of drug development services. It focuses on emulsions, gels, particulates and drug/device combination products with additional specialised capabilities in topical and mucosal drug delivery.
The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
